Rennova Health Inc  

(Public, NASDAQ:RNVA)   Watch this stock  
Find more results for NASDAQ:TGAL
-0.038 (-22.35%)
After Hours: 0.131 0.000 (0.00%)
Dec 9, 5:48PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.13 - 0.22
52 week 0.08 - 2.65
Open 0.21
Vol / Avg. 10.98M/2.55M
Mkt cap 9.88M
P/E 0.12
Div/yield     -
EPS 1.11
Shares 56.38M
Beta -0.47
Inst. own 8%
Nov 14, 2016
Q3 2016 Rennova Health Inc Earnings Release
Nov 14, 2016
Q3 2016 Rennova Health Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -4141.19% -195.52%
Operating margin -4336.82% -245.69%
EBITD margin - -122.72%
Return on average assets -337.43% -185.95%
Return on average equity - -1115.15%
Employees 185 -
CDP Score - -


400 S Australian Ave Ste 800
WEST PALM BEACH, FL 33401-5045
United States - Map
+1-561-8551626 (Phone)
+1-415-2485351 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova's principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.

Officers and directors

Seamus Lagan President, Chief Executive Officer, Interim Chief Financial Officer, Director
Age: 46
Bio & Compensation  - Reuters
Jeffrey L. Wadman Controller, Treasurer
Age: 59
Bio & Compensation  - Reuters
Sebastien Sainsbury Secretary
Bio & Compensation  - Reuters
Paul R Billings Director
Age: 63
Bio & Compensation  - Reuters
Christopher E. Diamantis Director
Age: 45
Bio & Compensation  - Reuters
Benjamin Frank Director
Bio & Compensation  - Reuters
Michael L. Goldberg Director
Age: 58
Bio & Compensation  - Reuters
Robert P. Lee Director
Age: 55
Bio & Compensation  - Reuters